AstraZeneca’s (AZN) Hold Rating Reiterated at Jefferies Financial Group
A number of other research firms also recently issued reports on AZN. Barclays reaffirmed an overweight rating on shares of AstraZeneca in a research note on Monday, January 21st. Goldman Sachs Group set a GBX 4,080 ($53.31) price target on shares of AstraZeneca and gave the company a sell rating in a research note on Tuesday, January 1st. JPMorgan Chase & Co. reaffirmed a buy rating on shares of AstraZeneca in a research note on Tuesday, January 22nd. Societe Generale upped their price target on shares of AstraZeneca from GBX 8,400 ($109.76) to GBX 8,500 ($111.07) and gave the company a buy rating in a research note on Wednesday, January 16th. Finally, Shore Capital reaffirmed a buy rating on shares of AstraZeneca in a research note on Monday, February 25th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have given a buy rating to the company’s stock. The company has an average rating of Buy and a consensus price target of GBX 6,282.20 ($82.09).
AZN stock opened at GBX 6,274 ($81.98) on Thursday. AstraZeneca has a one year low of GBX 4,746 ($62.01) and a one year high of GBX 6,432 ($84.05). The company has a current ratio of 0.96, a quick ratio of 0.71 and a debt-to-equity ratio of 136.31. The firm has a market capitalization of $79.51 billion and a PE ratio of 36.91.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Recommended Story: Liquidity
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.